1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Glioblastoma Multiforme Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Glioblastoma Multiforme Treatment Market, by Treatment
8.1.1 Surgery
8.1.1.1. Market Revenue and Forecast
8.1.2. Radiation Therapy
8.1.2.1. Market Revenue and Forecast
8.1.3. Chemotherapy
8.1.3.1. Market Revenue and Forecast
8.1.4. Targeted Therapy
8.1.4.1. Market Revenue and Forecast
8.1.5. Tumor Treating Field (TTF) Therapy
8.1.5.1. Market Revenue and Forecast
8.1.6. Immunotherapy
8.1.6.1. Market Revenue and Forecast
9.1. Glioblastoma Multiforme Treatment Market, by Drug Class
9.1.1. TMZ
9.1.1.1. Market Revenue and Forecast
9.1.2. Carboplatin
9.1.2.1. Market Revenue and Forecast
9.1.3. Cisplatin
9.1.3.1. Market Revenue and Forecast
9.1.4. Bevacizumab
9.1.4.1. Market Revenue and Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Forecast
10.1. Glioblastoma Multiforme Treatment Market, by End-user
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast
10.1.3. Ambulatory Surgical Centers
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Treatment
11.1.2. Market Revenue and Forecast, by Drug Class
11.1.3. Market Revenue and Forecast, by End-user
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Treatment
11.1.4.2. Market Revenue and Forecast, by Drug Class
11.1.4.3. Market Revenue and Forecast, by End-user
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Treatment
11.1.5.2. Market Revenue and Forecast, by Drug Class
11.1.5.3. Market Revenue and Forecast, by End-user
11.2. Europe
11.2.1. Market Revenue and Forecast, by Treatment
11.2.2. Market Revenue and Forecast, by Drug Class
11.2.3. Market Revenue and Forecast, by End-user
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Treatment
11.2.4.2. Market Revenue and Forecast, by Drug Class
11.2.4.3. Market Revenue and Forecast, by End-user
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Treatment
11.2.5.2. Market Revenue and Forecast, by Drug Class
11.2.5.3. Market Revenue and Forecast, by End-user
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Treatment
11.2.6.2. Market Revenue and Forecast, by Drug Class
11.2.6.3. Market Revenue and Forecast, by End-user
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Treatment
11.2.7.2. Market Revenue and Forecast, by Drug Class
11.2.7.3. Market Revenue and Forecast, by End-user
11.3. APAC
11.3.1. Market Revenue and Forecast, by Treatment
11.3.2. Market Revenue and Forecast, by Drug Class
11.3.3. Market Revenue and Forecast, by End-user
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Treatment
11.3.4.2. Market Revenue and Forecast, by Drug Class
11.3.4.3. Market Revenue and Forecast, by End-user
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Treatment
11.3.5.2. Market Revenue and Forecast, by Drug Class
11.3.5.3. Market Revenue and Forecast, by End-user
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Treatment
11.3.6.2. Market Revenue and Forecast, by Drug Class
11.3.6.3. Market Revenue and Forecast, by End-user
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Treatment
11.3.7.2. Market Revenue and Forecast, by Drug Class
11.3.7.3. Market Revenue and Forecast, by End-user
11.4. MEA
11.4.1. Market Revenue and Forecast, by Treatment
11.4.2. Market Revenue and Forecast, by Drug Class
11.4.3. Market Revenue and Forecast, by End-user
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Treatment
11.4.4.2. Market Revenue and Forecast, by Drug Class
11.4.4.3. Market Revenue and Forecast, by End-user
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Treatment
11.4.5.2. Market Revenue and Forecast, by Drug Class
11.4.5.3. Market Revenue and Forecast, by End-user
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Treatment
11.4.6.2. Market Revenue and Forecast, by Drug Class
11.4.6.3. Market Revenue and Forecast, by End-user
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Treatment
11.4.7.2. Market Revenue and Forecast, by Drug Class
11.4.7.3. Market Revenue and Forecast, by End-user
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Treatment
11.5.2. Market Revenue and Forecast, by Drug Class
11.5.3. Market Revenue and Forecast, by End-user
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Treatment
11.5.4.2. Market Revenue and Forecast, by Drug Class
11.5.4.3. Market Revenue and Forecast, by End-user
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Treatment
11.5.5.2. Market Revenue and Forecast, by Drug Class
11.5.5.3. Market Revenue and Forecast, by End-user
12.1. Merck & Co., Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Amgen, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. F. Hoffmann-La Roche Ltd.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Pfizer Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Teva Pharmaceutical Industries Ltd.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Sun Pharmaceutical Industries Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Arbor Pharmaceuticals, LLC
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Amneal Pharmaceuticals
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Karyopharm Therapeutics, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
